Using these transgenic mice, the development of HIF inhibitors or UCP1 activators as anti-obesity drugs may be facilitated, although low sensitivity due to the penetration depth in these mice remains a major obstacle to overcome. This evidence concerns the gene UCP1 and obesity due to melanocortin 4 receptor deficiency.